Induction of G1 arrest and apoptosis by Scutellaria barbata in the human promyelocytic leukemia HL-60 cell line

International Journal of Molecular Medicine

Volumn 20, Issue 1, 2007, Pages 123-128

  Kim, Eun Kyung ^a   Kwon, Kang Beom ^b   Han, Mi Jeong ^a   Song, Mi Young ^a   Lee, Ji Hyun ^a   Ko, Youn Suk ^b   Shin, Byung Cheal ^b   Yu, Jiahua ^a   Lee, Young Rae ^a   Ryu, Do Gon ^b   Park, Jin Woo ^a   Park, Byung Hyun ^a  

^a Chonbuk National University   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

Apoptosis; Cell cycle; HL 60 cell; Scutellaria barbata

Indexed keywords

DNA FRAGMENT; FORMAZAN; PLANT EXTRACT;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL STRAIN HL 60; DOSE RESPONSE; DRUG EFFECT; HUMAN; METABOLISM; PHYTOTHERAPY; PROMYELOCYTIC LEUKEMIA; SCUTELLARIA;

APOPTOSIS; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FORMAZANS; G1 PHASE; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; PHYTOTHERAPY; PLANT EXTRACTS; SCUTELLARIA;

EID: 34548107409     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.20.1.123     Document Type: Article

References (45)

1. Hartwell LH and Kastan MB: Cell cycle control and cancer. Science 266: 1821-1828, 1994.
2. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
3. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
4. Kato JY, Matsuoka M, Strom DK and Sherr CJ: Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol Cell Biol 14: 2713-2721, 1994.
5. 1 phase of the human cell cycle. Science 257: 1689-1694, 1992.
6. 2F transactivation by cyclin/cdk2 complexes. Genes Dev 8: 1772-1786, 1994.
7. 1 cyclin-dependent kinase activity. Genes Dev 9: 2873-2887, 1995.
8. Guadagno TM and Newport JW: Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity. Cell 84: 73-82, 1996.
9. Morgan DO: Principles of CDK regulation. Nature 374: 131-134, 1995.
10. Martinez JD, Stratagoules ED, LaRue JM, Powell AA, Gause PR, Craven MT, Payne CM, Powell MB, Gerner EW and Earnest DL: Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 31: 111-118, 1998.
11. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993.
12. Philchenkov A: Apoptosis, cancer therapy, and beyond. Cell Death Differ 13: 2004-2005, 2006.
13. Wyllie AH, Kerr JF and Currie AR: Cell death: the significance of apoptosis. Int Rev Cytol 68: 251-306, 1980.
14. Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5: 876-885, 2005.
15. Thornberry NA and Lazebnik Y: Caspases: enemies within. Science 281: 1312-1316, 1998.
16. Sakahira H, Enari M and Nagata S: Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 391: 96-99, 1998.
17. Cha YY, Lee EO, Lee HJ, Park YD, Ko SG, Kim DH, Kim HM, Kang IC and Kim SH: Methylene chloride fraction of Scutellaria barbata induces apoptosis in human U937 leukemia cells via the mitochondrial signaling pathway. Clin Chim Acta 348: 41-48, 2004.
18. Kwon KB, Yang JY, Ryu DG, Rho HW, Kim JS, Park JW, Kim HR and Park BH: Vibrio vulnificus cytolysin induces superoxide anion-initiated apoptotic signaling pathway in human ECV304 cells. J Biol Chem 276: 47518-47523, 2001.
19. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
20. Jacks T and Weinberg RA: Cell-cycle control and its watchman. Nature 381: 643-644, 1996.
21. 1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
22. Shukla S and Gupta S: Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol Carcinog 39: 114-126, 2004.
23. 2F complexes. Carcinogenesis 24: 555-563, 2003.
24. Lee YM and Sicinski P: Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. Cell Cycle 5: 2110-2114, 2006.
25. Shapiro GI: Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24: 1770-1783, 2006.
26. Buchkovich K, Duffy LA and Harlow E: The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58: 1097-1105, 1989.
27. 2F accumulation during cell growth and differentiation. Proc Natl Acad Sci USA 93: 3215-3220, 1996.
28. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ and Arnold A: The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev 20: 501-534, 1999.
29. Mueller A, Odze R, Jenkins TD, Shahsesfaei A, Nakagawa H, Inomoto T and Rustgi AK: A transgenic mouse model with cyclin D1 overexpression results in cell cycle, epidermal growth factor receptor, and p53 abnormalities. Cancer Res 57: 5542-5549, 1997.
30. Hunter T and Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
31. Gartel AL and Tyner AL: Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 246: 280-289, 1999.
32. Agarwal ML, Taylor WR, Chernov MV, Chernova OB and Stark GR: The p53 network. J Biol Chem 273: 1-4, 1998.
33. Danova M, Giordano M, Mazzini G and Riccardi A: Expression of p53 protein during the cell cycle measured by flow cytometry in human leukemia. Leuk Res 14: 417-422, 1990.
34. Howard CM, Claudio PP, De Luca A, Stiegler P, Jori FP, Safdar NM, Caputi M, Khalili K and Giordano A: Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27Kip1, and cyclin E negative feedback regulatory loop. Cancer Res 60: 2737-2744, 2000.
35. Paggi MG, Baldi A, Bonetto F and Giordano A: Retinoblastoma protein family in cell cycle and cancer: a review. J Cell Biochem 62: 418-430, 1996.
36. Strasser A, Harris AW, Jacks T and Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79: 329-339, 1994.
37. Gastman BR: Apoptosis and its clinical impact. Head Neck 23: 409-425, 2001.
38. Don MJ, Chang YH, Chen KK, Ho LK and Chau YP: Induction of CDK inhibitors (p21(WAF1) and p27(Kip1)) and Bak in the beta-lapachone-induced apoptosis of human prostate cancer cells. Mol Pharmacol 59: 784-794, 2001.
39. Deschler B and Lubbert M: Acute myeloid leukemia: Epidemiology and etiology. Cancer 107: 2099-2107, 2006.
40. Lengfelder E, Saussele S, Weisser A, Buchner T and Hehlmann R: Treatment concepts of acute promyelocytic leukemia. Crit Rev Oncol Hematol 56: 261-274, 2005.
41. Kwon KB, Yoo SJ, Ryu DG, Yang JY, Rho HW, Kim JS, Park JW, Kim HR and Park BH: Induction of apoptosis by diallyl disulfide through activation of caspase-3 in human leukemia HL-60 cells. Biochem Pharmacol 63: 41-47, 2002.
42. Kim R: Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 103: 1551-1560, 2005.
43. Martin KR: Targeting apoptosis with dietary bioactive agents. Exp Biol Med 231: 117-129, 2006.
44. Kwon KB, Park BH and Ryu DG: Chemotherapy through mitochondrial apoptosis using nutritional supplements and herbs: A brief overview. J Bioenerg Biomembr (In press).
45. Qu M, Xu H, Li Y and Luo H: An Illustrated Guide to Antineoplastic Chinese Herbal Medicine. 1st edition, The Commercial Press, Hong Kong, 1990.